CLASS II Drug recall · Reported 15 Jan 2020 · FDA Enforcement Report

Ranitidine 150 mg tablets, 130 count bottles recalled

AAA Pharmaceutical is recalling Ranitidine 150 mg tablets, 130 count bottles. The recall was initiated on 26 Dec 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesP134457, Sept 2020 P135156, Aug 2020 P135156, Aug 2020 P135243, Aug 2020 P135877, Sept 2020 P136145, Aug 2020 P136146, Sept 2020 P136623, April 2021 P136728, April, 2021 P136994, April, 2021 P137348, April, 2021 P137423, April, 2021 P137499, April, 2021
Quantity recalled31,536 (130-count bottles)

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0646-2020
FDA event ID
84583
Recalling firm
AAA Pharmaceutical, Lumberton, NJ
Classification
Class II
Status
Terminated
Recall initiated
26 Dec 2019
FDA classified
6 Jan 2020
Reported
15 Jan 2020
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity

Timeline

26 Dec 2019Recall initiated by company
6 Jan 2020Classified by FDA+11 days
15 Jan 2020Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Ranitidine 150 mg tablets, 130 count bottles, NDC 37808-196-04.

Where it was distributed

Product was distributed to one consignee who may have distributed the product further to their retail stores.

Questions about this recall

Is Ranitidine 150 mg tablets, 130 count bottles recalled?

Yes. AAA Pharmaceutical recalled Ranitidine 150 mg tablets, 130 count bottles on 26 Dec 2019. The recall is Class II and its status is Terminated. Recall number D-0646-2020.

Why was it recalled?

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Which lots are affected?

P134457, Sept 2020 P135156, Aug 2020 P135156, Aug 2020 P135243, Aug 2020 P135877, Sept 2020 P136145, Aug 2020 P136146, Sept 2020 P136623, April 2021 P136728, April, 2021 P136994, April, 2021 P137348, April, 2021 P137423, April, 2021 P137499, April, 2021

Where was it sold?

Product was distributed to one consignee who may have distributed the product further to their retail stores.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from AAA Pharmaceutical

All 4